Ameluz (aminolevulinic acid HCl)

Actinic Keratoses Agents Topical Gel (GRAM)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Aminolevulinic acid hydrochloride is the hydrochloride salt of 5-aminolevulinic acid, an endogenous precursor of protoporphyrin IX, which is a photosensitizer.

Aminolevulinic acid hydrochloride is the hydrochloride salt of 5-aminolevulinic acid, an endogenous precursor of protoporphyrin IX, which is a photosensitizer.

The formation of aminolevulinic acid from glycine and succinyl-coenzyme A (succinyl CoA) is the first step in the heme synthesis pathway; the final step is the incorporation of iron into protoporphyrin IX to form heme, which occurs under the action of ferrochelatase. The synthesis of aminolevulinic acid normally is tightly controlled by feedback inhibition of the enzyme aminolevulinic acid synthase, presumably by intracellular heme levels. Therefore, when exogenous aminolevulinic acid is provided to the cell through topical application of aminolevulinic acid hydrochloride, protoporphyrin IX accumulates because of the limited capacity of ferrochelatase to convert protoporphyrin IX into heme.

When exposed to light of appropriate wavelength and energy, the accumulated protoporphyrin IX produces a photodynamic reaction, a cytotoxic process dependent upon the simultaneous presence of light and oxygen. The absorption of light by protoporphyrin IX results in an excited state of the molecule and subsequent generation of cytotoxic singlet oxygen atoms, which can react further to form superoxide and hydroxyl radicals. The tissue-specific phototoxic effects resulting from local application of aminolevulinic acid hydrochloride and light irradiation are the basis of photodynamic therapy for actinic keratoses.

Generic name: aminolevulinic acid HCl
Drug class: Actinic Keratoses Agents
Therapeutic class: Dermatological

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Ameluz

Intelligence content is not available yet.

Indications

The following indications are listed for Ameluz:

  • Actinic Keratosis On The Face Or Scalp
  • Superficial Basal Cell Carcinoma

Also known as: Superficial Basal Cell Epithelioma, Superficial Basalioma, Superficial Bcc, Superficial Bce.

Dosing

No dosing information is available for this tab.

Drug interactions

No formal drug interaction studies have been performed. The manufacturer states that no drug-specific interactions were noted during any of the controlled clinical trials.

Contraindications

Known cutaneous photosensitivity at wavelengths of 400-450 nm, porphyria or known allergies to porphyrins, or known sensitivity to aminolevulinic acid hydrochloride or any ingredient in the formulation.

Adverse reactions

Transient local stinging and/or burning, itching, erythema, and edema were observed in all clinical trials of aminolevulinic acid hydrochloride topical solution plus BLU-U(R) blue light treatment. Severe stinging/burning of one or more lesions was reported in at least 50% of patients at some time during treatment, with most patients reporting at least slight stinging/burning of treated lesions. Less than 3% of patients in clinical trials discontinued light treatment because of stinging and/or burning. Erythema and edema at some or all lesions were reported in 99 or 35%, respectively, of patients shortly after treatment.

Precautions

No enhanced messaging available.

ICD codes

CodeTypeDescription
Actinic keratosis on the face or scalp
L57.0ICD10CMActinic keratosis
Superficial basal cell carcinoma
C44.01ICD10CMBasal cell carcinoma of skin of lip
C44.11ICD10CMBasal cell carcinoma of skin of eyelid, including canthus
C44.111ICD10CMBasal cell carcinoma of skin of unspecified eyelid, including canthus
C44.112ICD10CMBasal cell carcinoma of skin of right eyelid, including canthus
C44.1121ICD10CMBasal cell carcinoma of skin of right upper eyelid, including canthus
C44.1122ICD10CMBasal cell carcinoma of skin of right lower eyelid, including canthus
C44.119ICD10CMBasal cell carcinoma of skin of left eyelid, including canthus
C44.1191ICD10CMBasal cell carcinoma of skin of left upper eyelid, including canthus
C44.1192ICD10CMBasal cell carcinoma of skin of left lower eyelid, including canthus
C44.21ICD10CMBasal cell carcinoma of skin of ear and external auricular canal
C44.211ICD10CMBasal cell carcinoma of skin of unspecified ear and external auricular canal
C44.212ICD10CMBasal cell carcinoma of skin of right ear and external auricular canal
C44.219ICD10CMBasal cell carcinoma of skin of left ear and external auricular canal
C44.31ICD10CMBasal cell carcinoma of skin of other and unspecified parts of face
C44.310ICD10CMBasal cell carcinoma of skin of unspecified parts of face
C44.311ICD10CMBasal cell carcinoma of skin of nose
C44.319ICD10CMBasal cell carcinoma of skin of other parts of face
C44.41ICD10CMBasal cell carcinoma of skin of scalp and neck
C44.51ICD10CMBasal cell carcinoma of skin of trunk
C44.510ICD10CMBasal cell carcinoma of anal skin
C44.511ICD10CMBasal cell carcinoma of skin of breast
C44.519ICD10CMBasal cell carcinoma of skin of other part of trunk
C44.61ICD10CMBasal cell carcinoma of skin of upper limb, including shoulder
C44.611ICD10CMBasal cell carcinoma of skin of unspecified upper limb, including shoulder
C44.612ICD10CMBasal cell carcinoma of skin of right upper limb, including shoulder
C44.619ICD10CMBasal cell carcinoma of skin of left upper limb, including shoulder
C44.71ICD10CMBasal cell carcinoma of skin of lower limb, including hip
C44.711ICD10CMBasal cell carcinoma of skin of unspecified lower limb, including hip
C44.712ICD10CMBasal cell carcinoma of skin of right lower limb, including hip
C44.719ICD10CMBasal cell carcinoma of skin of left lower limb, including hip
C44.81ICD10CMBasal cell carcinoma of overlapping sites of skin
C44.91ICD10CMBasal cell carcinoma of skin, unspecified

ICD code information from First Databank (FDB).

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data